Iterum Therapeutics (ITRM)
(Delayed Data from NSDQ)
$1.25 USD
-0.01 (-0.40%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $1.24 -0.01 (-0.80%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
ITRM 1.25 -0.01(-0.40%)
Will ITRM be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ITRM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ITRM
Iterum (ITRM) Plans Early Submission of UTI Drug NDA, Stock Up
Avalo (AVTX) Fails to Meet Goal in Asthma Study, Stock Down 89%
ITRM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Catalyst (CPRX) to Gain DMD Drug Licensing Rights From Santhera
Beat the Market the Zacks Way: Uber, VirTra, Oracle in Focus
Baudax (BXRX) Up on New Neuromuscular Blocking Agent Study Data
Other News for ITRM
Iterum Therapeutics Commences Rights Offering
Iterum Therapeutics commences rights offering
Iterum to face AdCom as FDA reviews lead asset
Buy Rating Affirmed for Iterum Therapeutics on FDA Confidence and Market Opportunity
Iterum Therapeutics Announces FDA Advisory Committee Meeting to discuss NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections